Study of CM336 for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has returned or is not responding to treatment.
- You have tried at least two different treatments, including a proteasome inhibitor, an immunomodulatory drug, and a CD38-targeting antibody.
- Your disease shows signs of getting worse or didn't improve after your last treatment.
- Your myeloma can be measured by a specific blood or urine test at the start of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, CM336 and Isatuximab, for people newly diagnosed with multiple myeloma that has caused kidney damage. The goal is to see if this treatment can help control the myeloma while also addressing the kidney issues.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This study tests CM336, a new type of immunotherapy drug, for patients with multiple myeloma (a blood cancer) that has come back or progressed after their first treatment. The trial aims to see if this drug can help control the disease in patients at high risk of relapse.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.